Fas‐mediated lysis of chronic lymphocytic leukaemia cells: role of type I versus type II cytokines and autologous FasL‐expressing T cells

Authors:

Abstract
Given the known role of the fas cytolytic pathway in B‐cell regulation, we evaluated whether fas–fasL interactions might induce chronic lymphocytic leukaemia (CLL) cell death. De novo CLL cells expressed a low level of surface fas, and were not lysed by fasL‐bearing cells. CLL cells cultured in media containing the type I cytokines interleukin (IL)‐12 or interferon (IFN)‐α had increased fas expression, and were readily lysed by fasL‐bearing cells. In contrast, the type II cytokine IL‐4 did not increase CLL cell fas, and abrogated type I cytokine‐induced fas up‐regulation. With prolonged culture, IL‐4 exposed CLL cells expressed an intermediate level of fas; however, such CLL cells were resistant to fas‐mediated lysis. These results indicate that IL‐4 inhibits fas‐mediated killing of CLL cells at the level of both fas receptor expression and post‐receptor events. Additionally, we have defined in vitro culture conditions which generate fasL‐bearing T cells from CLL patients; such T cells efficiently mediated fas‐based lysis of autologous fas‐positive CLL cells. We therefore conclude that type I and type II cytokines differentially regulate the fas pathway in CLL cells, and that a combination of type I cytokines and fasL‐expressing T cells may represent a new approach to the immunotherapy of CLL.

This publication has 26 references indexed in Scilit: